Russian Journal of OncologyRussian Journal of OncologyРоссийский онкологический журнал1028-99842412-9119Eco-Vector4034610.18821/1028-9984-2017-22-6-300-306ArticlesСтатьиResearch ArticleTARGETED THERAPY OF NON-SMALL-CELL LUNG CANCER PATIENTS: MOST COMMON ADVERSE EVENTS AND METHODS OF THEIR CORRECTIONSТАРГЕТНАЯ ТЕРАПИЯ БОЛЬНЫХ НЕМЕЛКОКЛЕТОЧНЫМ РАКОМ ЛЁГКОГО: НАИБОЛЕЕ ЧАСТЫЕ ОСЛОЖНЕНИЯ И ПРИНЦИПЫ ИХ КОРРЕКЦИИReutovaElena V.РеутоваЕлена Валерьевна

MD, PhD, Senior Researcher of the Deparment of Clinical Biotechnology; Moscow, 115478, Russian Federation

канд. мед. наук, старший научный сотрудник отделения клинических биотехнологий; 115478, г. Москва, Каширское шоссе, д. 23

evreutova@rambler.ruLaktionovK. PЛактионовК. ПArdzinbaM. SАрдзинбаМ. СN.N. Blokhin National Medical Research Center of OncologyФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России15122017226VOL 22, NO6 (2017)ТОМ 22, №6 (2017)30030622072020Copyright ©; 2017, Eco-VectorCopyright ©; 2017, ООО "Эко-Вектор"2017Eco-VectorООО "Эко-Вектор"https://rjonco.com/1028-9984/article/view/40346

Major advances in the treatment of non-small-cell lung cancer (NSCLC) patients are associated with the targeted therapy. It is both highly effective in the presence of activating mutations in the tumor and generally well-tolerated. Serious adverse events are recorded much less than with chemotherapy. There are significant differences in the toxicity profile. Both early detection and proper and timely correction of complications of targeted therapies are necessary for the successful long-term treatment of metastatic NSCLC patients.

Основные успехи в лекарственном лечении больных немелкоклеточным раком лёгкого (НМРЛ) связаны с таргетной терапией. Она высокоэффективна при наличии активирующих мутаций в опухоли и в целом хорошо переносится. Серьёзные нежелательные явления регистрируются значительно реже, чем при проведении химиотерапии. Есть существенные отличия и в профиле токсичности. Раннее распознавание, правильная и своевременная коррекция осложнений таргетной терапии необходимы для успешного длительного лечения пациентов с диссеминированным НМРЛ.

non-small cell lung cancerEGFR mutationALK and ROS1 translocationinhibitors of EGFR/ALK and ROS1немелкоклеточный рак лёгкогомутации EGFRтранслокации ALK и ROS1ингибиторы EGFR/ALK и ROS1Perez-Moreno P., Brambilla E., Thomas R., Soria J.-C. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin. Cancer Res. 2012; 18(9); 1-9.Yang J.C.-H., Wu Y.-L., Schuler M. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology. 2015; 16(2): 141-51.Lu P.H., Kuo T.C., Chang K.C., Chang C.H., Chu C.Y. Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway. Br. J. Dermatol. 2011: 164(1), 38-46.Boone S.L., Rademaker A., Liu D., Pfeiffer C., Mauro D.J., Lacouture M.E. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007; 72(3-4): 152-9.Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361(10): 947-57.Han J.Y., Park K., Kim S.W., Lee D.H., Kim H.Y. et al. First-SIGNAL: first-line single-agent iressa versus gemcitabineand cisplatin trial in never-smokers with adenocarcinoma of the lung. J. Clin. Oncol. 2012; 30(10): 1122-8.Inoue A., Kobayashi K., Maemondo M., Sugawara S., Oizumi S., Isobe H. et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann. Oncol. 2013; 24(1): 54-9.Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010; 362(25): 2380-8.Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J. et al. Gefitinib versus cisplatin plus docetaxel in patients Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors 1347 with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology. 2010; 11(2): 121-8.Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology. 2011; 12(8):735-42.Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. 2012; 13(3): 239-46.Sequist L.V., Yang J.C., Yamamoto N., O’Byrne K., Hirsh V., Mok T. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 2013; 31(27): 3327-34.Wu Y.L., Zhou C., Hu C.P., Feng J., Lu S., Huang Y. et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomized phase 3 trial. Lancet Oncology. 2014; 15(2): 213-22.European Medicines Agency. Summary of Product Characterisitics-Tarceva (erlotinib). 2005 (2014 version accessed). cited. Available at: http://www.ema.europa.eu.European Medicines Agency. Summary of Product Characterisitics-Iressa (gefitinib). 2009 (2014 version accessed). cited; Available at: http://www.ema.europa.eu7.European Medicines Agency. Summary of Product Characterisitics-Giotrif (afatinib). 2014. cited; Available at: http://www.ema.europa.eu.Pomerantz R.G., Mirvish E.D., Geskin L.J. Cutaneous reactions to epidermal growth factor receptor inhibitors. J. Drugs Dermatol. 2010; 9(10): 1229-34.Uribe J.M., Gelbmann C.M., Traynor-Kaplan A.E., Barret K.E. Epidermal growth factor inhibits Ca(2 +)-dependent Cl-transport in T84 human colonic epithelial cells. Am. J. Physiol. 1996; 271(3 Pt 1): 914-22.Al-Dasooqi N., Gibson R., Bowen J., Keefe D. HER2 targeted therapies for cancer and the gastrointestinal tract. Curr. Drug Targets. 2009; 10(6): 537-42.Yang J.C., Reguart N., Barinoff J. et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert. Rev. Anticancer Ther. 2013; 13(6): 729-36.Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. 2012; 13(3): 239-46. doi: 10.1016/S1470-2045(11)70393-XGridelli C., De Marinis F., Di Maio M. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer. 2011; 71(3): 249-57.Passaro. A., Di Maio M., Del Signore E. et al. Management of Nonhematologic Toxicities Associated With Different EGFR-TKIs in Advanced NSCLC: A Comparison Analysis. Clinical Lung Cancer. 2014; 15(4): 307-12.Park K., Tan E.H., Zhang L. et al. Afatinib versus gefitinib as first-line treatment for patients with advanced non-small cell lung cancer harboring activating EGFR mutations: LUX-Lung 7. ESMO Asia. 2015: LBA2.5.Available at: http:// www.fda.gov/Drugs/InformationOnDrugs/../ucm472565.htmSolomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014; 371(23): 2167-77.Available at: http:// hcp.novartis.com/products/zykadia/alk-nsclc/safety-profile/Kuznar W. Upfront Alectinib Bests Crizotinib for ALK-Positive NSCLC. Targeted Oncology. Published Online: 3:28 PM, Mon June 13, 2016.Cappuzzo F., Moro-Sibilot D., Gautschi O., Boleti E., Felip E., Groen H.J. et al. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. Lung Cancer. 2015; 87(2): 89-95.Salgia R., Bolomon B. et al. Visual disturbances in patients (PTS) with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) treated with crizotinib (abstract 1268P). European Society Medical Oncology; 2012.Ramalingam S.S., Shaw A.T. Hypogonadism related to crizotinib therapy: implications for patient care. Cancer. 2012; 118(2): E1-2. DOI: 10.1002/cncr.27561Weickhardt A.J., Doebele R.C., Purcell W.T. et al. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013; 119(13): 2383-90. doi: 10.1002/cncr.28089Shaw A.T., Gandhi L., Gadgeel S., Bunn P.A., Oton A.B. et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016; 17(2): 234-42. doi: 10.1016/S1470-2045(15)00488-X.Food and drug administration. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdfLin Y.T., Wang Y.F., Yang J.C., Yu C.J., Wu S.G. et al. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J. Thorac. Oncol. 2014; 9(11): 1720-5.Inoue A., Xin H., Suzuki T. et al. Supression of surfactant protein A by an epidermal growth factor receptor tyrosinekinase inhibitor exacerbates lung inflamation. Cancer Sci. 2008; 99(8): 1679-84.Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2015/208065s000lbl.pdf (Accessed November 20, 2015).Kim D.-W., Tiseo M., Ahn M.-J., Reckamp K.L., Hansen K.H., Kim S.-W. et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J. Clin. Oncol. 2017; 35 (22): 2490-8.Reck M., Kaiser R., Mellemgaard A. et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncology. 2014; 15 (2): 143-55.